CliffBio
small molecule

DEFERASIROX

DEFERASIROX

Loss of exclusivity—loss of exclusivity
CompanyJEROME STEVENS PHARMACEUTICALS INC

Drug detail

Brand nameDEFERASIROX
Active ingredientDEFERASIROX
Strength90MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2019
Marketing statusDISCN

More from JEROME STEVENS PHARMACEUTICALS INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.